Malaria,Falciparum Clinical Trial
Official title:
A Phase 1b/2b Double Blind, Randomized, Controlled Study of the Safety, Immunogenicity, and Efficacy of Malaria Vaccine Candidate MSP3-CRM-Vac4All/ Alhydrogel® in Young Children in Mali
Two-arm, randomized, double-blinded and controlled clinical trial to first assess the safety and tolerability of the vaccine in a Phase 1b trial and proceed to assess its efficacy against clinical malaria in young children living in highly seasonal malaria areas of Mali
Status | Recruiting |
Enrollment | 465 |
Est. completion date | August 31, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Months to 59 Months |
Eligibility | Inclusion Criteria: - Children aged 12-59 months years old - Healthy by medical history, physical examination and laboratory investigation - Signed/thumb printed informed Consent by guardian/parent - Resident in the study area villages during the whole trial period Exclusion Criteria: - Symptoms, physical signs of disease that could interfere with the interpretation of the trial results or compromising the health of the participants - Immunosuppressive therapy (steroids, immune modulators or immune suppressors) within 3 months prior recruitment. (For corticosteroids, this will mean prednisone, or equivalent, more or equal to 0.5 mg/kg/day. Inhaled and topical steroids are allowed.) - Cannot be followed for any social, psychological or geographical reasons. - Use of any investigational drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use up to 30 days after the third dose. - Suspected or known hypersensitivity to any of the vaccine components or to previous vaccine. - Clinically significant laboratory abnormalities on screened blood samples. - Planned administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of vaccine. An exception, is the receipt of an childhood immunization program or licensed vaccine (measles, oral polio, Hib, meningococcal and combined diphtheria/pertussis/tetanus vaccines) which may be given before or after vaccination*. - Evidence of chronic or active hepatitis B or C infection - Presence of chronic illness that, in the judgment of the investigator, would interfere with the study outcomes or pose a threat to the participant's health. - Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period - History of surgical splenectomy. - Moderate or severe malnutrition at screening based on clinical judgement. o (Weight-for-age Z score of less than -3 or other clinical signs of malnutrition). - Previous participation to a malaria vaccine trial - Known history of HIV infection |
Country | Name | City | State |
---|---|---|---|
Mali | Malaria Research and Training Center (MRTC), University of Sciences Techniques and Technologies of Bamako, Mali | Bamako |
Lead Sponsor | Collaborator |
---|---|
Vac4All | Malaria Research and Training Center, Bamako, Mali |
Mali,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Protective Efficacy against Clinical Malaria | To assess the efficacy of 30 µg MSP3-CRM-Vac4All/Alhydrogel® vaccine in children ages 12-60 months old, against clinical malaria occurring over one transmission season.
The primary efficacy outcome is clinical malaria, with the primary case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of = 37.5ºC with P. falciparum parasitemia =5000/µL |
The timeline for assessment will be from 14 days to 6 months after Dose 3. | |
Secondary | Efficacy- different definitions of malaria fever and parasite thresholds on microscopy | To compare efficacy against clinical malaria for different case definitions using
Fever thresholds that are higher than 37.5ºC, such as 38.5ºC and 39.5ºC History of fever instead of measured fever Different parasitemia by microscopy thresholds [any parasitemia, 1000, 10,000 and 20,000/µL] Efficacy outcomes clinical malaria episodes defined as a febrile episode with an axillary temperature of = 38.5ºC with P. falciparum parasitemia =5000/µL or = 39.5ºC with P. falciparum parasitemia =5000/µL or clinical malaria episodes defined as history of fever with P. falciparum parasitemia of the following levels: any parasitemia, 1000, 10,000 and 20,000/µL clinical malaria episodes defined as a febrile episode with an axillary temperature of = 38.5ºC with or = 39.5ºC with P. falciparum parasitemia of the following levels: any parasitemia, 1000, 10,000 and 20,000/µL |
For 12 months after first vaccination | |
Secondary | Efficacy duration | To assess the efficacy of MSP3-CRM-Vac4All/Alhydrogel® in young children against clinical malaria occurring during the 12 months following dose 3. | For 12 months following the first vaccination | |
Secondary | Efficacy against first malaria episodes | To assess the efficacy of MSP3-CRM-Vac4All/Alhydrogel® in young children against first clinical malaria episodes occurring from over the 6 month period 14 days after 2nd and 3rd vaccination and up to the end of study follow-up (12 months after first vaccination).
The efficacy outcome is first episode of clinical malaria, with the case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of = 37.5ºC with P. falciparum parasitemia =5000/µL |
From 14 days post 2nd or 3rd vaccination to 6 months following and up to the end of study follow-up (12 months after first vaccination | |
Secondary | Efficacy (conditional boost) | To assess the efficacy of MSP3-CRM-Vac4All/Alhydrogel® in young children against clinical malaria occurring The efficacy outcome is clinical malaria, with the primary case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of = 37.5ºC with P. falciparum parasitemia =5000/µL | For the 6 months following boost vaccination | |
Secondary | Efficacy (conditional boost) | To assess the efficacy of MSP3-CRM-Vac4All/Alhydrogel® in young children against clinical malaria occurring.
The efficacy outcome is clinical malaria, with the primary case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of = 37.5ºC with P. falciparum parasitemia =5000/µL |
For the 12 months following boost vaccination | |
Secondary | Number of adverse events | To assess the safety and reactogenicity of 3 doses of 30 µg MSP3-CRM-Vac4All/Alhydrogel® given at D0, D28 and D56 in healthy young children | During the month following each vaccination, and 6 months and 12 months after first vaccination. | |
Secondary | Number of adverse events for conditional boost vaccination | Safety and reactogenicity of boost vaccination doses of MSP3-CRM-Vac4All/Alhydrogel® in healthy young children | At one month, 6 month and 12 months following boost vaccination | |
Secondary | Immune response | To examine the duration of immune responses of a 3-dose regimen of during periods corresponding to that used for primary and other secondary efficacy endpoints as measured through a > 5-fold decrease of MSP3-specific serum IgG antibody titers after each vaccination in comparison to baseline levels (14 days post last dose) | From 14 days post last dose to up to a month after last dose, 6 months after last dose and 12 months after first dose | |
Secondary | Immune response | To determine immunogenicity in terms of the proportion with titres either more than 3SD above the median for negative controls (positive) or at least 50% of the positive controls (strongly positive) after dose 3. | A month after dose 3 | |
Secondary | Parasite densities | To measure effect on parasitemia by comparing parasite densities in malaria episodes occurring in vaccinees compared to control | From vaccination to up to 6 months after last dose and 12 months after first dose. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04130282 -
VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine
|
Phase 1 | |
Completed |
NCT04049916 -
Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03814616 -
Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections
|
Phase 2 | |
Active, not recruiting |
NCT04079621 -
Short Course Radical Cure of P. Vivax Malaria in Nepal
|
Phase 4 | |
Completed |
NCT05135273 -
Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali
|
Phase 1 | |
Not yet recruiting |
NCT06083688 -
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi
|
Phase 4 | |
Recruiting |
NCT03511443 -
Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections
|
N/A | |
Completed |
NCT05550909 -
Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali
|
Phase 2 | |
Recruiting |
NCT05306067 -
Plasmodium Falciparum Genomic Intelligence in Mozambique
|
||
Completed |
NCT05081089 -
Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali
|
Phase 2 | |
Recruiting |
NCT05150808 -
Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania
|
Phase 3 | |
Recruiting |
NCT05757167 -
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics
|
Phase 4 | |
Completed |
NCT01992900 -
A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria
|
Phase 2 | |
Completed |
NCT04565184 -
Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde
|
Phase 4 | |
Completed |
NCT03896724 -
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
|
Phase 1/Phase 2 | |
Completed |
NCT03454048 -
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
|
N/A | |
Recruiting |
NCT04844905 -
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
|
Phase 3 | |
Completed |
NCT03138096 -
Safety and Protective Efficacy of Pb(PfCS@UIS4)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04271306 -
Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.
|
Phase 1 | |
Recruiting |
NCT05058885 -
Plasmodium Vivax Among Duffy Negative Population in Cameroon.
|